Yu-ting Gan
Chongqing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Efficacy and Safety of Baricitinib in Refractory Juvenile Dermatomyositis: A Retrospective Study.
Journal: American journal of therapeutics
Published: August 28, 2026
Efficacy and Safety of Abrocitinib in the Treatment of Prurigo Nodularis: A Real-World Study.
Journal: American journal of therapeutics
Published: August 27, 2026
Upadacitinib for Chronic Spontaneous Urticaria: A Retrospective Study.
Journal: American journal of therapeutics
Published: July 23, 2026
Salvage Therapy With Upadacitinib for Tofacitinib-Refractory Scarring Alopecia in an Asian Patient: Role of JAK1 Selective Inhibition.
Journal: American journal of therapeutics
Published: June 15, 2026
Tofacitinib for Pigmented Purpuric Dermatoses: Subtype-Specific Therapeutic Responses and Clinical Implications.
Journal: American journal of therapeutics
Published: June 15, 2026
Tislelizumab-Associated Bullous Pemphigoid.
Journal: American journal of therapeutics
Published: March 23, 2026
Tofacitinib in Pigmented Purpuric Dermatoses.
Journal: American journal of therapeutics
Published: February 27, 2026
Tislelizumab-Associated Vitiligo.
Journal: American journal of therapeutics
Published: February 16, 2026
Envafolimab-Associated Toxic Epidermal Necrolysis.
Journal: American journal of therapeutics
Published: February 11, 2026
Sintilimab-Associated Vitiligo.
Journal: American journal of therapeutics
Published: December 17, 2025
Oral JAK Inhibitors in Adolescent Vitiligo: A Real-World Retrospective Study on Treatment Response and Recurrence.
Journal: Journal of the American Academy of Dermatology
Published: December 04, 2025
Tofacitinib for Acquired Reactive Perforating Collagenosis: A Retrospective Study of Efficacy and Safety.
Journal: International journal of dermatology
Published: November 18, 2025
Last Updated: 09/26/2026